Noxxon AG Report issue

For profit Phase 1 Phase 2
Founded: Berlin Germany (1997)

Organization Overview

First Clinical Trial
2009
NCT00976729
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

NOXXON Pharma AG

Active Ingredients

Drugs in Phase 2 Trials (4)

lexaptepid pegol (4 trials)

nox-e36 (4 trials)

olaptesed pegol (Spiegelmer) (7 trials)

pembrolizumab (keytruda) (1 trial)

Drugs in Phase 1 Trials (2)

glucose (1 trial)

sargramostim (leukine) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Albuminuria (Phase 2)

Anemia (Phase 2)

Chronic Disease (Phase 2)

Colorectal Neoplasms (Phase 2)

Diabetes Mellitus (Phase 2)

Diabetes Mellitus, Type 2 (Phase 2)

Endotoxemia (Phase 1)

Glioblastoma (Phase 2)

Inflammation (Phase 1)

Kidney Failure, Chronic (Phase 2)

Leukemia (Phase 2)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)

Leukemia, Lymphoid (Phase 2)

Lupus Erythematosus, Systemic (Phase 1)

Multiple Myeloma (Phase 2)

Neoplasms, Plasma Cell (Phase 2)

Pancreatic Neoplasms (Phase 2)

Renal Insufficiency (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 15
  • # of Trial APIs: 6